TriMaster: randomised double-blind crossover study of a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as second-line or third-line therapy in patients with type 2 diabetes who have suboptimal glycaemic control on metformin treatment with or without a sulfonylurea—a MASTERMIND study protocol
Introduction Pharmaceutical treatment options for patients with type 2 diabetes mellitus (T2DM) have increased to include multiple classes of oral glucose-lowering agents but without accompanying guidance on which of these may most benefit individual patients. Clinicians lack information for treatme...
Main Authors: | Rury R Holman, Catherine Angwin, Christopher Jennison, Caroline Jenkinson |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2020-12-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/10/12/e042784.full |
Similar Items
-
Cardiovascular Safety of SGLT2 Inhibitors Compared to DPP4 Inhibitors and Sulfonylureas as the Second-Line of Therapy in T2DM Using Large, Real-World Clinical Data in Korea
by: Kyuho Kim, et al.
Published: (2021-07-01) -
Quantitative Evaluation of Compliance with Recommendation for Sulfonylurea Dose Co-Administered with DPP-4 Inhibitors in Japan
by: Motonobu Sakaguchi, et al.
Published: (2012-09-01) -
SGLT2 Inhibitors, GLP-1 Agonists, and DPP-4 Inhibitors in Diabetes and Microvascular Complications: A Review
by: Christopher El Mouhayyar, et al.
Published: (2020-01-01) -
A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes
by: Seon-Ah Cha, et al.
Published: (2017-04-01) -
DPP4i, thiazolidinediones, or insulin and risks of cancer in patients with type 2 diabetes mellitus on metformin–sulfonylurea dual therapy with inadequate control
by: Esther W Y Chan, et al.
Published: (2020-04-01)